Part 9/11:
The convergence of AI and genomics heralds a new era in healthcare. Advances in multiomics, DNA sequencing, and synthesis are drastically reducing costs and timelines for genetic analysis—reading a genome now takes less than 10 minutes. This rapid progress enables early disease detection, personalized medicine, and curative therapies, marking a shift from reactive to proactive healthcare.
Crisper Therapeutics exemplifies this revolution, pioneering gene editing treatments such as Crispr-based cures for sickle cell disease. The potential for these therapies to become standard care, coupled with improved reimbursement and adoption, could revolutionize treatment paradigms.